Idiopathic Pulmonary Fibrosis in Switzerland: Diagnosis and Treatment

Publikation

Idiopathic Pulmonary Fibrosis in Switzerland: Diagnosis and Treatment

Wissenschaftlicher Artikel/Review - 25.03.2017

Funke-Chambour Manuela, Geiser Thomas, Tamm Michael, Soccal Paola M, Nicod Laurent P, Kleiner-Finger Rebekka, Hostettler Katrin, Clarenbach Christian F, Brutsche Martin, Bridevaux Pierre-Olivier, Boehler Annette, Benden Christian, Barazzone-Argiroffo Constance, Adler Dan, Azzola Andrea, Lazor Romain

Zitation

Funke-Chambour M, Geiser T, Tamm M, Soccal P, Nicod L, Kleiner-Finger R, Hostettler K, Clarenbach C, Brutsche M, Bridevaux P, Boehler A, Benden C, Barazzone-Argiroffo C, Adler D, Azzola A, Lazor R. Idiopathic Pulmonary Fibrosis in Switzerland: Diagnosis and Treatment. Respiration 2017; 93:363-378.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Respiration 2017; 93

Veröffentlichungsdatum

25.03.2017

eISSN (Online)

1423-0356

Seiten

363-378

Kurzbeschreibung/Zielsetzung

Idiopathic pulmonary fibrosis (IPF) is a severe progressive and irreversible lung disease. Novel antifibrotic drugs that slow disease progression are now available. However, many issues regarding patient management remain unanswered, such as the choice between available drugs, their use in particular subgroups and clinical situations, time of treatment onset, termination, combination or switch, or nonpharmacologic management. To guide Swiss respiratory physicians in this evolving field still characterized by numerous areas of uncertainty, the Swiss Working Group for interstitial and rare lung diseases of the Swiss Respiratory Society provides a position paper on the diagnosis and treatment of IPF.